reports
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences DUBLIN, Ireland, March 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Leerink Global Biopharma Conference: Fireside chat on Wednesday, March 12 at 9:20 a.m. ET.UBS Virtual CNS Day: Fireside chat on Monday, March 17 at 8:30 a.m. ET. A live webcast of these events, as well as archived recordings, will be availab...
Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Q...
Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial Results -- LUMRYZ™ generated $50.4 million in sales in the fourth quarter, up 158% year-over-year, taking the full-year total to $169.1 million, in line with preliminary results published January 8 -- Reiterates 2025 guidance, with the number of patients on LUMRYZ expected to increase to 3,300-3,500 by year-end, generating $240-$260 million in net product revenue and cash flow of $20-40 million -- Executing multiple initiatives to accelerate patient demand for LUMRYZ -- Patient enr...
TG Therapeutics Provides Business Update and Reports Fourth Quarter an...
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results Fourth quarter and full year 2024 BRIUMVI U.S. net revenue of $103.6 million and $310 million, respectively Target guidance of approximately $540 million in total global revenue for 2025 Conference call to be held today, March 3, 2025, at 8:30 AM ET NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results ...
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Resul...
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025 DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, 2025. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call....
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multipl...
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in West Palm Beach, ...
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Yea...
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update Conference call to be held Monday, March 3, 2025, at 8:30 AM ET NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, March 3, 2025, at 8:30 AM ET to discuss results for the fourth quarter and full year 2024 and to provide a business outlook for 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please cal...
Interparfums, Inc. Reports Record 2024 Fourth Quarter and Full Year Re...
Interparfums, Inc. Reports Record 2024 Fourth Quarter and Full Year Results Achieves Diluted EPS of $5.12;Diluted EPS Before Impairment of $5.18 Exceeds Expectations;Reaffirms 2025 Guidance and Announces 7% Increase in Cash Dividend NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Interparfums, Inc. (NASDAQ GS: IPAR) today reported record results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter & Full Year Highlights: ($ in millions, except per share amounts)Three Months EndedDecember 31,Year EndedDecember 31,20242023% Change20242023% ChangeNet Sales$362$32910%$1,4...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3 DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, March 3, 2025, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2024. A live audio webcast of the call can be accessed by v...
Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of S...
Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that Kevin Springman has joined the company as Vice President of Sales. Mr. Springman is an accomplished executive with experience leading sales, market access and commercial teams, and executing rare disease drug launches in competitive markets. "We’re delighted to welcome Kevin to Avadel – he’s a great addition to our team with the deep e...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule ...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to five (5) new employees to purchase 173,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® ...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS) to be presented at the upcoming Americas Committee for Treatment and Research in Mul...
RGC Resources, Inc. Reports First Quarter Earnings
RGC Resources, Inc. Reports First Quarter Earnings ROANOKE, Va., Feb. 10, 2025 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (Nasdaq: RGCO) announced consolidated Company earnings of $5,269,689, or $0.51 per share, for the first quarter ended December 31, 2024, compared to $5,019,992, or $0.50 per share, for the fiscal quarter ended December 31, 2023. Higher utility margin reflected the new base rates that went into effect July 1, 2024 and was offset by lower equity earnings from unconsolidated affiliate and higher interest expense. Roanoke Gas continued investing in utility infrastructure...
Full House Resorts Announces Fourth Quarter Earnings Release Date
Full House Resorts Announces Fourth Quarter Earnings Release Date LAS VEGAS, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Full House Resorts (NASDAQ: FLL) announced today that it will report its fourth quarter 2024 and full-year financial results on Thursday, March 6, 2025, followed by a conference call at 4:30 p.m. ET (1:30 p.m. PT). Investors can access the live audio webcast from the Company’s website at under the investor relations section. The conference call can also be accessed by dialing (201) 689-8470. A replay of the conference call will be available shortly after the conclusion of the ...
RGC Resources, Inc. Schedules First Quarter 2025 Earnings Call
RGC Resources, Inc. Schedules First Quarter 2025 Earnings Call ROANOKE, Va., Jan. 28, 2025 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (NASDAQ: RGCO) will host its quarterly conference call and webcast to review the results of its fiscal first quarter 2025 on Tuesday, February 11, 2025 at 9:00 a.m. eastern time. Related presentation materials will be available before the call on the Company website on the Investor & Financial Information page at . Interested parties may access the conference call by dialing toll-free 1-877-304-9269 and entering conference identification number 917621. An arc...
RGC Resources Holds Annual Shareholders Meeting
RGC Resources Holds Annual Shareholders Meeting ROANOKE, Va., Jan. 27, 2025 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (NASDAQ: RGCO) announced the election of Directors at its shareholders meeting held on January 27, 2025. Shareholders elected Abney S. Boxley III, Elizabeth A. McClanahan and John B. Williamson III for three-year terms. Shareholders also ratified the appointment of Deloitte & Touche, LLP as auditors for fiscal 2025. At a meeting of the Board of Directors, following the annual shareholders meeting, John B. Williamson III was elected Chairman of the Board and Paul W. N...
Interparfums, Inc. Reports Record 2024 Fourth Quarter and Full Year Ne...
Interparfums, Inc. Reports Record 2024 Fourth Quarter and Full Year Net Sales Achieves FY2024 Net Sales of $1.45 Billion2024 Fourth Quarter& Full Year Conference Call Scheduled for February 26, 2025 NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums” or the “Company”) today announced that for the three months and full year ended December 31, 2024, net sales rose 10% to $362 million and 10% to $1.45 billion, from the same periods in 2023, respectively. Net Sales ($ in millions) Three Months EndedYear EndedDecember 31,December 31, 2024 ...
Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Pat...
Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement DUBLIN, Ireland, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Sev Melkonian has joined the company as Vice President of Patient Services, Distribution, and Reimbursement. Mr. Melkonian has extensive industry experience building and leading healthcare operations and patient support service teams across global healthcare and biopharmaceutical ...
Avadel Pharmaceuticals: 2 directors
Two Directors at Avadel Pharmaceuticals bought 40,000 shares at between 7.841USD and 8.045USD. The significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.